# reload+after+2024-01-20 06:43:08.057708
address1§245 Hammersmith Road
city§London
zip§W6 8PW
country§United Kingdom
phone§44 20 8154 4600
website§https://www.achillestx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
fullTimeEmployees§234
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Iraj  Ali', 'age': 47, 'title': 'CEO & Director', 'yearBorn': 1976, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Karl Stuart Peggs M.D.', 'age': 56, 'title': 'Founder & Chief Medical Officer', 'yearBorn': 1967, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D.', 'age': 60, 'title': 'Founder', 'yearBorn': 1963, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Charles  Swanton FMEDSCI, M.D., Ph.D.', 'age': 50, 'title': 'Founder', 'yearBorn': 1973, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sergio A. Quezada Ph.D.', 'age': 47, 'title': 'Founder & Chief Scientific Officer', 'yearBorn': 1976, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert  Coutts', 'age': 39, 'title': 'Chief Financial Officer', 'yearBorn': 1984, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Lee M. Stern', 'title': 'Vice President of Investor Relations & External Communications', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Daniel Carey Cazel Hood', 'title': 'General Counsel & Company Secretary', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Julia  Wilson', 'title': 'Head of Communications', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Tariq  Ahmed', 'title': 'Executive Vice President of People', 'exercisedValue': 0, 'unexercisedValue': 0}]
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.87
currency§USD
dateShortInterest§1702598400
forwardEps§-1.25
pegRatio§-0.09
exchange§NMS
quoteType§EQUITY
shortName§Achilles Therapeutics plc
longName§Achilles Therapeutics plc
firstTradeDateEpochUtc§1617197400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§cd1224e6-3b8c-3fc4-8e0c-3cb68aaed9cf
gmtOffSetMilliseconds§-18000000
targetHighPrice§11.0
targetLowPrice§0.5
targetMeanPrice§6.88
targetMedianPrice§8.0
recommendationMean§2.2
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§8.236
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
